US20070027083A1 - Human growth hormone aqueous formulation - Google Patents
Human growth hormone aqueous formulation Download PDFInfo
- Publication number
- US20070027083A1 US20070027083A1 US11/529,677 US52967706A US2007027083A1 US 20070027083 A1 US20070027083 A1 US 20070027083A1 US 52967706 A US52967706 A US 52967706A US 2007027083 A1 US2007027083 A1 US 2007027083A1
- Authority
- US
- United States
- Prior art keywords
- formulation
- polysorbate
- growth hormone
- hgh
- ionic surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention is directed to pharmaceutical formulations containing human growth hormone (hGH) and to methods for making and using such formulations. More particularly, this invention relates to such pharmaceutical formulations having increased stability in aqueous formulation.
- hGH human growth hormone
- Protropin® hGH consists of 5 mg hGH, 40 mg mannitol, 0.1 mg monobasic sodium phosphate, 1.6 mg dibasic sodium phosphate, reconstituted to pH 7.8 ( Physician's Desk Reference , Medical Economics Co., Orawell, N.J., p. 1049, 1992).
- Humatrope® hGH consists of 5 mg hGH, 25 mg mannitol, 5 mg glycine, 1.13 mg dibasic sodium phosphate, reconstituted to pH 7.5 ( Physician's Desk Reference , p. 1266, 1992).
- U.S. Pat. No. 4,297,344 discloses stabilization of coagulation factors II and VIII, antithrombin III, and plasminogen against heat by adding selected amino acids such as glycine, alanine, hydroxyproline, glutamine, and aminobutyric acid, and a carbohydrate such as a monosaccharide, an oligosaccharide, or a sugar alcohol.
- U.S. Pat. No. 4,783,441 discloses a method for the prevention of denaturation of proteins such as insulin in aqueous solution at interfaces by the addition of up to 500 ppm surface-active substances comprising a chain of alternating, weakly hydrophilic and weakly hydrophobic zones at pH 6.8-8.0.
- U.S. Pat. No. 4,812,557 discloses a method of stabilization of interleukin-2 using human serum albumin.
- European Patent Application Publication No. 0 303 746 discloses stabilization of growth promoting hormones with polyols consisting of non-reducing sugars, sugar alcohols, sugar acids, pentaerythritol, lactose, water-soluble dextrans, and Ficoll, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts.
- European Patent Application Publication No. 0 211 601 discloses the stabilization of growth promoting hormones in a gel matrix formed by a block copolymer containing polyoxyethylene-polyoxypropylene units and having an average molecular weight of about 1,100 to about 40,000.
- European Patent Application Publication No. 0 193 917 discloses a biologically active composition for slow release characterized by a water solution of a complex between a protein and a carbohydrate.
- U.S. Pat. No. 5,096,885 discloses a formulation of hGH for lyophilization containing glycine, mannitol, a non-ionic surfactant, and a buffer.
- the instant invention provides an unexpectedly stabilized aqueous formulation in the absence of glycine.
- hGH undergoes several degradative pathways, especially deamidation, aggregation, clipping of the peptide backbone, and oxidation of methionine residues. Many of these reactions can be slowed significantly by removal of water from the protein.
- an aqueous formulation for hGH has the advantages of eliminating reconstitution errors, thereby increasing dosing accuracy, as well as simplifying the use of the product clinically, thereby increasing patient compliance.
- One aspect of the invention is a stable, pharmaceutically acceptable, aqueous formulation of human growth hormone comprising human growth hormone, a buffer, a non-ionic surfactant, and optionally, a neutral salt, mannitol, and a preservative.
- a further aspect of the invention is a method of preventing denaturation of human growth hormone aqueous formulations comprising mixing human growth hormone and a non-ionic surfactant in the range of 0.1-5% (w/v) (weight/volume).
- this stabilized formulation is stored for 6-18 months at 2-8° C.
- FIG. 1 is a size exclusion chromatogram of aqueous growth hormone formulation stored for 28 days at 40° C. (i.e., thermally stressed) and for one year at 5° C. (i.e., recommended conditions for storage).
- FIG. 2 is a plot of Arrhenius rate analysis of growth hormone aggregation in aqueous formulation.
- FIG. 3 is an anion exchange chromatogram comparing a thermally stressed (40° C.) aqueous formulation hGH sample with an aqueous formulation hGH sample stored under recommended conditions (2-8° C.) for one year.
- FIG. 4 is a plot of Arrhenius rate analysis of hGH deamidation in aqueous formulation.
- FIG. 5 is a graph of the percentage monomer present in the various formulations where mannitol has been substituted with a neutral salt.
- human growth hormone denote human growth hormone produced by methods including natural source extraction and purification, and by recombinant cell culture systems. Its sequence and characteristics are set forth, for example, in Hormone Drugs , Gueriguian et al., U.S.P. Convention, Rockville, Md. (1982). The terms likewise cover biologically active human growth hormone equivalents, e.g., differing in one or more amino acid(s) in the overall sequence. Furthermore, the terms used in this application are intended to cover substitution, deletion and insertion amino acid variants of hGH, or posttranslational modifications. Two species of note are the 191 amino acid native species (somatropin) and the 192 amino acid N-terminal methionine (met) species (somatrem) commonly obtained recombinantly.
- hGH human growth hormone produced by methods including natural source extraction and purification, and by recombinant cell culture systems. Its sequence and characteristics are set forth, for example, in Hormone Drugs , Gueriguian
- compositions hereof are prepared containing amounts of hGH at least about 0.1 mg/ml, upwards of about 10 mg/ml, preferably from about 1 mg/ml to about 20 mg/ml, more preferably from about 1 mg/ml to about 5 mg/ml.
- these compositions contain from about 0.1 mg/ml to about 10 mg/ml, corresponding to the currently contemplated dosage regimen for the intended treatment.
- concentration range is not critical to the invention, and may be varied by the clinician.
- the instant invention has no requirement for glycine.
- Glycine is an optional component of the aqueous formulation, although with less advantage in the aqueous formulations hereof compared with those formulations that are lyophilized for later reconstitution. Amounts of glycine will range from 0 mg/ml to about 7 mg/ml.
- Non-ionic surfactants include a polysorbate, such as polysorbate 20 or 80, etc., and the poloxamers, such as poloxamer 184 or 188, Pluronic® polyols, and other ethylene/polypropylene block polymers, etc. Amounts effective to provide a stable, aqueous formulation will be used, usually in the range of from about 0.1% (w/v) to about 5% (w/v), more preferably, 0.1% (w/v) to about 1% (w/v).
- the use of non-ionic surfactants permits the formulation to be exposed to shear and surface stresses without causing denaturation of the protein.
- such surfactant-containing formulations are employed in aerosol devices such as those used in pulmonary dosing and needleless jet injector guns.
- Buffers include phosphate, Tris, citrate, succinate, acetate, or histidine buffers. Most advantageously, the buffer is in the range of about 2 mM to about 50 mM.
- the preferred buffer is a sodium citrate buffer.
- a preservative is included in the formulation to retard microbial growth and thereby allow “multiple use” packaging of the hGH.
- Preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, benzalconium chloride, and benzethonium chloride.
- the preferred preservatives include 0.2-0.4% (w/v) phenol and 0.7-1% (w/v) benzyl alcohol.
- Suitable pH ranges, adjusted with buffer, for aqueous hGH formulation are from about 4 to 8, more preferably about 5.5 to about 7, most advantageously 6.0.
- a buffer concentration range is chosen to minimize deamidation, aggregation, and precipitation of hGH.
- Mannitol may optionally be included in the aqueous hGH formulation.
- the preferred amount of mannitol is about 5 mg/ml to about 50 mg/ml.
- other sugars or sugar alcohols are used, such as lactose, trehalose, stachiose, sorbitol, xylitol, ribitol, myo-inositol, galactitol, and the like.
- Neutral salts such as sodium chloride or potassium chloride are optionally used in place of sugars or sugar alcohols.
- the salt concentration is adjusted to near isotonicity, depending on the other ingredients present in the formulation.
- concentration range of NaCl may be 50-200 mM, depending on the other ingredients present.
- the formulation of the subject invention comprises the following components at pH 6.0.
- polysorbate 80 or a poloxamer
- a succinate or acetate buffer could instead be employed, and alternative preservatives and different pHs could be used.
- more than one buffering agent, preservative, sugar, neutral salt, or non-ionic surfactant may be used.
- the formulation is isotonic and sterile.
- the formulations of the subject invention may contain other components in amounts not detracting from the preparation of stable forms and in amounts suitable for effective, safe pharmaceutical administration.
- other pharmaceutically acceptable excipients well known to those skilled in the art may form a part of the subject compositions. These include, for example, various bulking agents, additional buffering agents, chelating agents, antioxidants, cosolvents and the like; specific examples of these could include trimethylamine salts (“Tris buffer”), and disodium edetate.
- HPIEC Anion exchange chromatography
- Nondenaturing size exclusion chromatography was run on a TSK 2000 SWXL column in 50 mM sodium phosphate, pH 7.2 containing 150 mM sodium chloride. The flow rate was 1 ml/min, with a 50-75 ⁇ g column load and detection at either 214 and 280 nm.
- Denaturing size exclusion chromatography was run on a Zorbax GF250 column in 200 mM sodium phosphate, pH 6.8-7.2/0.1% SDS. The flow rate was 1.0 ml/minute, with a with a 50-75 ⁇ g column load and detection at either 214 and 280 nm.
- aqueous hGH formulation samples for analysis in these experimental examples were prepared by buffer exchange on a gel filtration column.
- the elution buffer contained either sodium chloride or mannitol, buffer and the non-ionic surfactant in their final ratios.
- This resulting solution was diluted to a desired hGH concentration and the preservative was added.
- the solution was sterile filtered using a sterilized membrane filter (0.2 micron pore size or equivalent) and filled into sterile 3 cc type 1 glass vials, stoppered and sealed with aqueous-type butyl rubber stoppers and aluminum flip-off type caps.
- the aqueous hGH formulation used in the experimental examples consisted of 5.0 mg somatropin (Genentech, Inc.), 45.0 mg mannitol, 2.5 mg phenol, 2.0 mg polysorbate 20, and 2.5 mg sodium citrate, pH 6.0, per ml of solution.
- the lyophilized formulation used as a reference for comparison in the examples consisted of 5.0 mg somatropin, 1.7 mg glycine, 45.0 mg mannitol, 1.7 mg sodium phosphate, 9 mg benzyl alcohol per ml sterile solution after reconstitution.
- Vials of the hGH aqueous formulation were incubated at either recommended storage temperatures of 2-8° C., or elevated storage temperatures of 15° C., or 25° C., and then removed at various time points and assayed for changes in pH, color and appearance, and protein concentration. In addition, samples were incubated at 40° C. in order to study degradation patterns under extreme stress conditions. Degradation patterns for the aqueous formulation were also compared to the known degradation patterns for lyophilized growth hormone.
- the amount of degradation product was calculated as an area percentage of the total hGH area of the chromatogram.
- the rate constant for each reaction was then calculated by subtracting the percentage of degradation product from 100%, taking the log 10 , and plotting against the time in days. The slope of a straight line to fit these data was used as the reaction constant (k).
- Arrhenius analysis was done by plotting the natural logarithm (ln) of the absolute value of each calculated reaction rate constant at 15, 25, and 40° C. as a function of the inverse absolute temperature and then extrapolating to 5° C.
- Arrhenius and real time rate analysis ( FIG. 2 ) of data from the size exclusion HPLC indicate that the amount of growth hormone aggregation after 18 months of storage will be less than 1% (w/v).
- Each of six vials of lyophilized growth hormone were reconstituted with 1 ml bacteriostatic water for injection (BWFI) U.S.P. After dissolving, the contents were transferred to 3 cc vials, stoppered, and capped to provide the same configuration as that for the aqueous formulation.
- BWFI bacteriostatic water for injection
- the six vials of the hGH aqueous formulation and six vials of reconstituted lyophilized hGH were vigorously shaken top to bottom in a horizontal fashion on a Glas-Col Shaker-in-the-Round at 240 jolts per minute using a stroke setting of 2.5, giving a horizontal displacement of 8 ⁇ 1 cm for up to 24 hours at room temperature to assess the effects of agitation on physical stability of the hGH aqueous formulation. All twelve samples were placed in a straight line on the shaker to assure that they were all exposed to the same force for each formulation. Two vials were removed for assays at 30 minutes, 6 hours, and 24 hours.
- hGH aqueous formulation samples were subjected to bacterial challenge according to an abbreviated challenge using the standard U.S.P. test.
- a suspension of either E. coli or S. aureus was added to an aliquot of hGH aqueous formulation to give a final concentration of bacteria between 10 5 to 10 6 CFU/ml.
- Viable bacteria remaining in the tubes were counted immediately and after 4 and 24 hours incubation at 20-25° C.
- composition 42 0.1% (w/v) polysorbate 20 50 mM mannitol 47 0.1% (w/v) poloxamer/188 0.1 M NaCl 51 0.5% (w/v) polysorbate 20 50 mM mannitol 52 0.1% (w/v) poloxamer 188 50 mM mannitol 53 0.1% (w/v) poloxamer 184 50 mM mannitol 60 0.2% (w/v) polysorbate 20 0.1 M NaCl 61 0.2% (w/v) polysorbate 20 0.05 M NaCl 62 0.2% (w/v) polysorbate 20 0.15 M NaCl 63 0.2% (w/v) polysorbate 20 50 mM mannitol
Abstract
A stable pharmaceutically acceptable aqueous formulation containing human growth hormone, a buffer, a non-ionic surfactant, and, optionally, a neutral salt, mannitol, or, a preservative, is disclosed. Also disclosed are associated means and methods for preparing, storing, and using such formulations.
Description
- The present invention is directed to pharmaceutical formulations containing human growth hormone (hGH) and to methods for making and using such formulations. More particularly, this invention relates to such pharmaceutical formulations having increased stability in aqueous formulation.
- Human growth hormone formulations known in the art are all lyophilized preparations requiring reconstitution. Per vial, Protropin® hGH consists of 5 mg hGH, 40 mg mannitol, 0.1 mg monobasic sodium phosphate, 1.6 mg dibasic sodium phosphate, reconstituted to pH 7.8 (Physician's Desk Reference, Medical Economics Co., Orawell, N.J., p. 1049, 1992). Per vial, Humatrope® hGH consists of 5 mg hGH, 25 mg mannitol, 5 mg glycine, 1.13 mg dibasic sodium phosphate, reconstituted to pH 7.5 (Physician's Desk Reference, p. 1266, 1992).
- For a general review for growth hormone formulations, see Pearlman et al., Current Communications in Molecular Biolocry, eds. D. Marshak and D. Liu, pp. 23-30, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989. Other publications of interest regarding stabilization of proteins are as follows.
- U.S. Pat. No. 4,297,344 discloses stabilization of coagulation factors II and VIII, antithrombin III, and plasminogen against heat by adding selected amino acids such as glycine, alanine, hydroxyproline, glutamine, and aminobutyric acid, and a carbohydrate such as a monosaccharide, an oligosaccharide, or a sugar alcohol.
- U.S. Pat. No. 4,783,441 discloses a method for the prevention of denaturation of proteins such as insulin in aqueous solution at interfaces by the addition of up to 500 ppm surface-active substances comprising a chain of alternating, weakly hydrophilic and weakly hydrophobic zones at pH 6.8-8.0.
- U.S. Pat. No. 4,812,557 discloses a method of stabilization of interleukin-2 using human serum albumin.
- European Patent Application Publication No. 0 303 746 discloses stabilization of growth promoting hormones with polyols consisting of non-reducing sugars, sugar alcohols, sugar acids, pentaerythritol, lactose, water-soluble dextrans, and Ficoll, amino acids, polymers of amino acids having a charged side group at physiological pH, and choline salts.
- European Patent Application Publication No. 0 211 601 discloses the stabilization of growth promoting hormones in a gel matrix formed by a block copolymer containing polyoxyethylene-polyoxypropylene units and having an average molecular weight of about 1,100 to about 40,000.
- European Patent Application Publication No. 0 193 917 discloses a biologically active composition for slow release characterized by a water solution of a complex between a protein and a carbohydrate.
- Australian Patent Application No. AU-A-30771/89 discloses stabilization of growth hormone using glycine and mannitol.
- U.S. Pat. No. 5,096,885 (which is not prior art) discloses a formulation of hGH for lyophilization containing glycine, mannitol, a non-ionic surfactant, and a buffer. The instant invention provides an unexpectedly stabilized aqueous formulation in the absence of glycine.
- hGH undergoes several degradative pathways, especially deamidation, aggregation, clipping of the peptide backbone, and oxidation of methionine residues. Many of these reactions can be slowed significantly by removal of water from the protein. However, the development of an aqueous formulation for hGH has the advantages of eliminating reconstitution errors, thereby increasing dosing accuracy, as well as simplifying the use of the product clinically, thereby increasing patient compliance. Thus, it is an objective of this invention to provide an aqueous hGH formulation which provides acceptable control of degradation products, is stable to vigorous agitation (which induces aggregation), and is resistant to microbial contamination (which allows multiple use packaging).
- One aspect of the invention is a stable, pharmaceutically acceptable, aqueous formulation of human growth hormone comprising human growth hormone, a buffer, a non-ionic surfactant, and optionally, a neutral salt, mannitol, and a preservative.
- A further aspect of the invention is a method of preventing denaturation of human growth hormone aqueous formulations comprising mixing human growth hormone and a non-ionic surfactant in the range of 0.1-5% (w/v) (weight/volume). In yet another aspect of the invention, this stabilized formulation is stored for 6-18 months at 2-8° C.
-
FIG. 1 is a size exclusion chromatogram of aqueous growth hormone formulation stored for 28 days at 40° C. (i.e., thermally stressed) and for one year at 5° C. (i.e., recommended conditions for storage). -
FIG. 2 is a plot of Arrhenius rate analysis of growth hormone aggregation in aqueous formulation. -
FIG. 3 is an anion exchange chromatogram comparing a thermally stressed (40° C.) aqueous formulation hGH sample with an aqueous formulation hGH sample stored under recommended conditions (2-8° C.) for one year. -
FIG. 4 is a plot of Arrhenius rate analysis of hGH deamidation in aqueous formulation. -
FIG. 5 is a graph of the percentage monomer present in the various formulations where mannitol has been substituted with a neutral salt. - A. Definitions
- The following terms are intended to have the indicated meanings denoted below as used in the specification and claims.
- The terms “human growth hormone” or “hGH” denote human growth hormone produced by methods including natural source extraction and purification, and by recombinant cell culture systems. Its sequence and characteristics are set forth, for example, in Hormone Drugs, Gueriguian et al., U.S.P. Convention, Rockville, Md. (1982). The terms likewise cover biologically active human growth hormone equivalents, e.g., differing in one or more amino acid(s) in the overall sequence. Furthermore, the terms used in this application are intended to cover substitution, deletion and insertion amino acid variants of hGH, or posttranslational modifications. Two species of note are the 191 amino acid native species (somatropin) and the 192 amino acid N-terminal methionine (met) species (somatrem) commonly obtained recombinantly.
- The term “pharmaceutically effective amount” of hGH refers to that amount that provides therapeutic effect in an administration regimen. The compositions hereof are prepared containing amounts of hGH at least about 0.1 mg/ml, upwards of about 10 mg/ml, preferably from about 1 mg/ml to about 20 mg/ml, more preferably from about 1 mg/ml to about 5 mg/ml. For use of these compositions in administration to human patients suffering from hypopituitary dwarfism, for example, these compositions contain from about 0.1 mg/ml to about 10 mg/ml, corresponding to the currently contemplated dosage regimen for the intended treatment. The concentration range is not critical to the invention, and may be varied by the clinician.
- B. General Methods
- The instant invention has no requirement for glycine. Glycine is an optional component of the aqueous formulation, although with less advantage in the aqueous formulations hereof compared with those formulations that are lyophilized for later reconstitution. Amounts of glycine will range from 0 mg/ml to about 7 mg/ml.
- Non-ionic surfactants include a polysorbate, such as
polysorbate 20 or 80, etc., and the poloxamers, such as poloxamer 184 or 188, Pluronic® polyols, and other ethylene/polypropylene block polymers, etc. Amounts effective to provide a stable, aqueous formulation will be used, usually in the range of from about 0.1% (w/v) to about 5% (w/v), more preferably, 0.1% (w/v) to about 1% (w/v). The use of non-ionic surfactants permits the formulation to be exposed to shear and surface stresses without causing denaturation of the protein. For example, such surfactant-containing formulations are employed in aerosol devices such as those used in pulmonary dosing and needleless jet injector guns. - Buffers include phosphate, Tris, citrate, succinate, acetate, or histidine buffers. Most advantageously, the buffer is in the range of about 2 mM to about 50 mM. The preferred buffer is a sodium citrate buffer.
- A preservative is included in the formulation to retard microbial growth and thereby allow “multiple use” packaging of the hGH. Preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, benzalconium chloride, and benzethonium chloride. The preferred preservatives include 0.2-0.4% (w/v) phenol and 0.7-1% (w/v) benzyl alcohol.
- Suitable pH ranges, adjusted with buffer, for aqueous hGH formulation are from about 4 to 8, more preferably about 5.5 to about 7, most advantageously 6.0. Preferably, a buffer concentration range is chosen to minimize deamidation, aggregation, and precipitation of hGH.
- Mannitol may optionally be included in the aqueous hGH formulation. The preferred amount of mannitol is about 5 mg/ml to about 50 mg/ml. As an alternative to mannitol, other sugars or sugar alcohols are used, such as lactose, trehalose, stachiose, sorbitol, xylitol, ribitol, myo-inositol, galactitol, and the like.
- Neutral salts such as sodium chloride or potassium chloride are optionally used in place of sugars or sugar alcohols. The salt concentration is adjusted to near isotonicity, depending on the other ingredients present in the formulation. For example, the concentration range of NaCl may be 50-200 mM, depending on the other ingredients present.
- In a preferred embodiment, the formulation of the subject invention comprises the following components at pH 6.0.
Ingredient Quantity (mg) hGH 5 Sodium Chloride 8.8 Polysorbate 20 2.0 Sodium citrates 2.5 Phenol 2.5 Sterile water 1 ml - It will be understood that the above quantities are somewhat flexible within ranges, as set forth in more detail above, and that the materials are interchangeable within the component categories. That is, polysorbate 80, or a poloxamer, may be substituted for
polysorbate 20, a succinate or acetate buffer could instead be employed, and alternative preservatives and different pHs could be used. In addition, more than one buffering agent, preservative, sugar, neutral salt, or non-ionic surfactant may be used. Preferably, the formulation is isotonic and sterile. - In general, the formulations of the subject invention may contain other components in amounts not detracting from the preparation of stable forms and in amounts suitable for effective, safe pharmaceutical administration. For example, other pharmaceutically acceptable excipients well known to those skilled in the art may form a part of the subject compositions. These include, for example, various bulking agents, additional buffering agents, chelating agents, antioxidants, cosolvents and the like; specific examples of these could include trimethylamine salts (“Tris buffer”), and disodium edetate.
- Anion exchange chromatography (HPIEC) was run on a TSK DEAE 5PW column (1.0×7.5 cm) at 45° C. with a flow rate of 0.5 ml/min. The column was equilibrated in 50 mM potassium phosphate, pH 5.5, containing 10% (w/v) acetonitrile. Elution was performed using a 25 minute gradient from 50-100 mM potassium phosphate, pH 5.5 with constant 10% (w/v) acetonitrile. The column load was 83 μg of protein. Detection was at 230 nM.
- Nondenaturing size exclusion chromatography was run on a TSK 2000 SWXL column in 50 mM sodium phosphate, pH 7.2 containing 150 mM sodium chloride. The flow rate was 1 ml/min, with a 50-75 μg column load and detection at either 214 and 280 nm.
- Denaturing size exclusion chromatography was run on a Zorbax GF250 column in 200 mM sodium phosphate, pH 6.8-7.2/0.1% SDS. The flow rate was 1.0 ml/minute, with a with a 50-75 μg column load and detection at either 214 and 280 nm.
- In general, aqueous hGH formulation samples for analysis in these experimental examples were prepared by buffer exchange on a gel filtration column. The elution buffer contained either sodium chloride or mannitol, buffer and the non-ionic surfactant in their final ratios. This resulting solution was diluted to a desired hGH concentration and the preservative was added. The solution was sterile filtered using a sterilized membrane filter (0.2 micron pore size or equivalent) and filled into sterile 3 cc type 1 glass vials, stoppered and sealed with aqueous-type butyl rubber stoppers and aluminum flip-off type caps.
- The aqueous hGH formulation used in the experimental examples consisted of 5.0 mg somatropin (Genentech, Inc.), 45.0 mg mannitol, 2.5 mg phenol, 2.0
mg polysorbate 20, and 2.5 mg sodium citrate, pH 6.0, per ml of solution. The lyophilized formulation used as a reference for comparison in the examples consisted of 5.0 mg somatropin, 1.7 mg glycine, 45.0 mg mannitol, 1.7 mg sodium phosphate, 9 mg benzyl alcohol per ml sterile solution after reconstitution. - Vials of the hGH aqueous formulation (lots 12738/55-102 and 12738/55-105) were incubated at either recommended storage temperatures of 2-8° C., or elevated storage temperatures of 15° C., or 25° C., and then removed at various time points and assayed for changes in pH, color and appearance, and protein concentration. In addition, samples were incubated at 40° C. in order to study degradation patterns under extreme stress conditions. Degradation patterns for the aqueous formulation were also compared to the known degradation patterns for lyophilized growth hormone.
- After storage at 2-8° C. for up to one year, the aqueous formulation showed insignificant changes in pH, color and appearance, and protein concentration. Nondenaturing size exclusion HPLC performed on samples stored for up to one year at 2-8° C. showed no significant aggregation of the drug product (
FIG. 1 ). This result is unexpected in light of the teaching of U.S. Pat. No. 5,096,885 that glycine contributes to preventing aggregation in the lyophilized preparation. - At temperatures above 8° C., little or no changes in pH or protein concentration were observed over time. Visual inspection revealed an increase in opalescence with time for samples stored at 40° C. This change was minimal during storage at 15-25° C. and has not been observed during 2-8° C. storage.
- The amount of degradation product was calculated as an area percentage of the total hGH area of the chromatogram. The rate constant for each reaction was then calculated by subtracting the percentage of degradation product from 100%, taking the log10, and plotting against the time in days. The slope of a straight line to fit these data was used as the reaction constant (k). Arrhenius analysis was done by plotting the natural logarithm (ln) of the absolute value of each calculated reaction rate constant at 15, 25, and 40° C. as a function of the inverse absolute temperature and then extrapolating to 5° C. Arrhenius and real time rate analysis (
FIG. 2 ) of data from the size exclusion HPLC indicate that the amount of growth hormone aggregation after 18 months of storage will be less than 1% (w/v). - Anion exchange HPLC analysis performed on the aqueous hGH formulation stored at 40° C. indicated an increase in acidic peaks over 28 days (
FIG. 3 ). Three of these peaks, eluting at about 16, 17.5, and 26 minutes, were produced by hGH deamidation atpositions plus 152. Arrhenius and real time rate analysis (FIG. 4 ) of data from this method, were plotted as described above, and indicate that the amount of deamidated hGH in these lots after 18 months of storage at 2-8° C. will be about 9% (w/v). This includes an initial amount of about 2.4% (w/v) deamidated hGH at time zero. Values as high as 15% (w/v) deamidation have been reported for other hGH products (Larhammar, H., et al., (1985) Int. J. Pharmaceutics 23:13-23). Although the rate of deamidation is faster in the aqueous state, this rate is minimized at pH 6.0 and below. - Each of six vials of lyophilized growth hormone were reconstituted with 1 ml bacteriostatic water for injection (BWFI) U.S.P. After dissolving, the contents were transferred to 3 cc vials, stoppered, and capped to provide the same configuration as that for the aqueous formulation. The six vials of the hGH aqueous formulation and six vials of reconstituted lyophilized hGH were vigorously shaken top to bottom in a horizontal fashion on a Glas-Col Shaker-in-the-Round at 240 jolts per minute using a stroke setting of 2.5, giving a horizontal displacement of 8±1 cm for up to 24 hours at room temperature to assess the effects of agitation on physical stability of the hGH aqueous formulation. All twelve samples were placed in a straight line on the shaker to assure that they were all exposed to the same force for each formulation. Two vials were removed for assays at 30 minutes, 6 hours, and 24 hours.
- The results are displayed in Table I. Agitation produced very little change in the visual clarity of the aqueous formulation. There was no change in the content of total growth hormone monomer as detected by a nondenaturing size exclusion HPLC assay. This assay detects noncovalent aggregates, which are completely dispersed by SDS in a denaturing size exclusion HPLC assay.
- By comparison, these results also demonstrated that the reconstituted lyophilized product was more sensitive to treatment, even after only 30 minutes of shaking. This sensitivity is typical for all currently available formulations of hGH, other than the aqueous formulation of the instant invention. The inclusion of the non-ionic surfactant is the most important factor in preventing this phenomenon from occurring.
TABLE I Effects of Agitation at Room Temperature on hGH Aqueous Formulation vs. Reconstituted Lyophilized Formulation % % HPSEC Soluble % Total1 Sample Color/Appearance Monomer Protein Monomer Unshaken Aqueous clear/colorless 99.7 ND ND Aqueous clear/colorless 99.9 ND ND Lyophilized clear/colorless 99.0 100 99.0 Lyophilized clear/colorless ND ND ND Shaken 0.5 hr Aqueous very slightly 99.9 100 99.9 opalescent/colorless Aqueous very slightly 100.0 100 100.0 opalescent/colorless Lyophilized slightly 93.6 100 93.6 opalescent/colorless Lyophilized clear/colorless 92.8 100 92.8 Shaken 6 hr Aqueous slightly 99.9 100 99.9 opalescent/colorless Aqueous opalescent/colorless 99.8 100 99.8 Lyophilized very 80.5 73 58.8 opalescent/yellow to brown Lyophilized very 72.7 61.7 44.9 opalescent/yellow to brown Shaken 24 hr Aqueous slightly 99.8 100 99.8 opalescent/colorless Aqueous clear/colorless 99.8 ND ND Lyophilized very cloudy/yellow 60.6 21.5 13.0 to brown Lyophilized very cloudy/yellow 56.7 14.8 8.4 to brown
1Total monomer = (% monomer × % soluble protein)/100
- Samples of hGH aqueous formulation were subjected to bacterial challenge according to an abbreviated challenge using the standard U.S.P. test. In this test, a suspension of either E. coli or S. aureus was added to an aliquot of hGH aqueous formulation to give a final concentration of bacteria between 105 to 106 CFU/ml. Viable bacteria remaining in the tubes were counted immediately and after 4 and 24 hours incubation at 20-25° C. The percentage change in the concentration of the microorganisms during the challenge was calculated according to the following equation:
- The results of this experiment indicated that for two species of bacteria, concentrations of viable bacteria were reduced to less than 0.01% of the initial concentrations after 24 hours.
- In this experiment aqueous formulations of hGH were compared that varied in concentrations of salt, mannitol, and non-ionic surfactant. All formulations contained 5 mg/ml hGH/0.25% (w/v) phenol/10 mM sodium citrate, pH 6.0. Samples were stored 3-4 months at 2-8° C.
FIG. 5 indicates the percentage monomer present in the indicated formulations. The Table below indicates the composition of each formulation. These results demonstrate the unexpected stability of hGH in a formulation in which mannitol has been substituted with a neutral salt in the presence of a surfactant.TABLE 3 Formulations Tested in FIG. 5 Formulation # Composition 42 0.1% (w/v) polysorbate 2050 mM mannitol 47 0.1% (w/v) poloxamer/188 0.1 M NaCl 51 0.5% (w/v) polysorbate 2050 mM mannitol 52 0.1% (w/v) poloxamer 188 50 mM mannitol 53 0.1% (w/v) poloxamer 184 50 mM mannitol 60 0.2% (w/v) polysorbate 200.1 M NaCl 61 0.2% (w/v) polysorbate 200.05 M NaCl 62 0.2% (w/v) polysorbate 200.15 M NaCl 63 0.2% (w/v) polysorbate 2050 mM mannitol
Claims (21)
1. A stable pharmaceutically acceptable aqueous formulation of human growth hormone comprising:
a) human growth hormone,
b) a buffer
c) a non-ionic surfactant,
d) optionally, mannitol,
e) optionally, a neutral salt, and
f) optionally, a preservative.
2. The formulation of claim 1 wherein the non-ionic surfactant is present in the range of about 0.1% (w/v) to about 1% (w/v).
3. The formulation of claim 1 wherein the non-ionic surfactant is a poloxamer.
4. The formulation of claim 1 wherein the non-ionic surfactant is a polysorbate.
5. The formulation of claim 3 wherein the poloxamer is poloxamer 188 or poloxamer 184.
6. The formulation of claim 4 wherein the polysorbate is polysorbate 20 or polysorbate 80.
7. The formulation of claim 1 wherein the concentration of mannitol is about 5 mg/ml to about 50 mg/ml.
8. The formulation of claim 1 wherein the buffer is a citrate buffer.
9. The formulation of claim 1 wherein the buffer concentration is about 2 mM to about 50 mM.
10. The formulation of claim 1 wherein the buffer is selected from the group consisting of phosphate, Tris, succinate, acetate, or histidine buffers.
11. The formulation of claim 1 wherein the formulation is sterile.
12. The formulation of claim 1 wherein the formulation is isotonic.
13. The formulation of claim 1 wherein the neutral salt is sodium chloride.
14. The formulation of claim 1 wherein the preservative is selected from the group consisting of phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, benzalconium chloride, and benzethonium chloride.
15. An aqueous hGH formulation comprising 5 mg/ml hGH, 8.8 mg/ml sodium chloride, 2.0 mg/ml polysorbate 20, 2.5 mg/ml sodium citrate, and 2.5 mg/ml phenol, at pH 6.0.
16. A method of preventing denaturation of human growth hormone aqueous formulations comprising mixing human growth hormone and a non-ionic surfactant in the range of 0.1-5% (w/v).
17. The method of claim 16 wherein the non-ionic surfactant is a poloxamer.
18. The method of claim 16 wherein the non-ionic surfactant is a polysorbate.
19. The method of claim 17 wherein the poloxamer is poloxamer 188 or 184.
20. The method of claim 18 wherein the polysorbate is polysorbate 20 or polysorbate 80.
21. A method of preventing denaturation of human growth hormone aqueous formulations stored for six to 18 months at 2-8° C. comprising mixing human growth hormone and a non-ionic surfactant in the range of 0.1-5% (w/v).
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/529,677 US20070027083A1 (en) | 1988-04-15 | 2006-09-28 | Human growth hormone aqueous formulation |
US12/321,084 US20090163419A1 (en) | 1988-04-15 | 2009-01-15 | Human growth hormone aqueous formulation |
US13/150,911 US20110230408A1 (en) | 1988-04-15 | 2011-06-01 | Human growth hormone aqueous formulation |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/182,262 US5096885A (en) | 1988-04-15 | 1988-04-15 | Human growth hormone formulation |
US75142491A | 1991-08-28 | 1991-08-28 | |
US92340192A | 1992-07-31 | 1992-07-31 | |
PCT/US1993/007149 WO1994003198A1 (en) | 1992-07-31 | 1993-07-29 | Human growth hormone aqueous formulation |
US08/117,156 US5763394A (en) | 1988-04-15 | 1993-07-29 | Human growth hormone aqueous formulation |
US08/891,823 US5981485A (en) | 1997-07-14 | 1997-07-14 | Human growth hormone aqueous formulation |
US09/344,225 US6448225B2 (en) | 1988-04-15 | 1999-06-25 | Human growth hormone aqueous formulation |
US10/186,775 US20030013653A1 (en) | 1988-04-15 | 2002-07-01 | Human growth hormone aqueous formulation |
US11/199,314 US20050272657A1 (en) | 1988-04-15 | 2005-08-08 | Human growth hormone aqueous formulation |
US11/529,677 US20070027083A1 (en) | 1988-04-15 | 2006-09-28 | Human growth hormone aqueous formulation |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/199,314 Continuation US20050272657A1 (en) | 1988-04-15 | 2005-08-08 | Human growth hormone aqueous formulation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/321,084 Continuation US20090163419A1 (en) | 1988-04-15 | 2009-01-15 | Human growth hormone aqueous formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070027083A1 true US20070027083A1 (en) | 2007-02-01 |
Family
ID=25398881
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/891,823 Expired - Lifetime US5981485A (en) | 1988-04-15 | 1997-07-14 | Human growth hormone aqueous formulation |
US09/344,225 Expired - Fee Related US6448225B2 (en) | 1988-04-15 | 1999-06-25 | Human growth hormone aqueous formulation |
US10/186,775 Abandoned US20030013653A1 (en) | 1988-04-15 | 2002-07-01 | Human growth hormone aqueous formulation |
US11/199,314 Abandoned US20050272657A1 (en) | 1988-04-15 | 2005-08-08 | Human growth hormone aqueous formulation |
US11/529,677 Abandoned US20070027083A1 (en) | 1988-04-15 | 2006-09-28 | Human growth hormone aqueous formulation |
US12/321,084 Abandoned US20090163419A1 (en) | 1988-04-15 | 2009-01-15 | Human growth hormone aqueous formulation |
US13/150,911 Abandoned US20110230408A1 (en) | 1988-04-15 | 2011-06-01 | Human growth hormone aqueous formulation |
US13/772,773 Abandoned US20130165378A1 (en) | 1997-07-14 | 2013-02-21 | Method of treating human growth hormone mediated condition |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/891,823 Expired - Lifetime US5981485A (en) | 1988-04-15 | 1997-07-14 | Human growth hormone aqueous formulation |
US09/344,225 Expired - Fee Related US6448225B2 (en) | 1988-04-15 | 1999-06-25 | Human growth hormone aqueous formulation |
US10/186,775 Abandoned US20030013653A1 (en) | 1988-04-15 | 2002-07-01 | Human growth hormone aqueous formulation |
US11/199,314 Abandoned US20050272657A1 (en) | 1988-04-15 | 2005-08-08 | Human growth hormone aqueous formulation |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/321,084 Abandoned US20090163419A1 (en) | 1988-04-15 | 2009-01-15 | Human growth hormone aqueous formulation |
US13/150,911 Abandoned US20110230408A1 (en) | 1988-04-15 | 2011-06-01 | Human growth hormone aqueous formulation |
US13/772,773 Abandoned US20130165378A1 (en) | 1997-07-14 | 2013-02-21 | Method of treating human growth hormone mediated condition |
Country Status (1)
Country | Link |
---|---|
US (8) | US5981485A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180206890A1 (en) * | 2017-01-25 | 2018-07-26 | Warsaw Orthopedic, Inc | Spinal implant system and methods of use |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981485A (en) * | 1997-07-14 | 1999-11-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US20070179096A1 (en) * | 1996-04-24 | 2007-08-02 | Novo Nordisk A/S | Pharmaceutical Formulation |
US20030162711A1 (en) * | 1996-04-24 | 2003-08-28 | Soren Bjorn | Pharmaceutical formulation |
SE9801495D0 (en) * | 1998-04-28 | 1998-04-28 | Astra Ab | Protein formulation |
US6387711B1 (en) * | 2000-08-11 | 2002-05-14 | Quest Diagnostics Investments Incorporated | Liquid intact parathyroid hormone (PTH) standards |
US6905886B2 (en) * | 2000-08-11 | 2005-06-14 | Quest Diagnostics Investments Incorporated | Preservative solutions |
GB2371227A (en) * | 2001-01-10 | 2002-07-24 | Grandis Biotech Gmbh | Crystallisation - resistant aqueous growth hormone formulations |
WO2002092619A2 (en) * | 2001-05-14 | 2002-11-21 | The Gouvernment Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Modified growth hormone |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20050163725A1 (en) * | 2002-03-20 | 2005-07-28 | Blizzard Charles D. | Method for administration of growth hormone via pulmonary delivery |
CA2478327A1 (en) * | 2002-03-20 | 2003-10-02 | Advanced Inhalation Research, Inc. | Hgh (human growth hormone) formulations for pulmonary administration |
US7008644B2 (en) * | 2002-03-20 | 2006-03-07 | Advanced Inhalation Research, Inc. | Method and apparatus for producing dry particles |
AR040526A1 (en) * | 2002-07-09 | 2005-04-13 | Grandis Biotech Gmbh | HGH FORMULATIONS IN HIGH CONCENTRATION CONTAINING PHENOL |
US20070065469A1 (en) * | 2002-07-09 | 2007-03-22 | Michael Betz | Liquid formulations with high concentration of human growth hormone (high) comprising glycine |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
SG176314A1 (en) * | 2002-12-31 | 2011-12-29 | Altus Pharmaceuticals Inc | Human growth hormone crystals and methods for preparing them |
WO2004071439A2 (en) | 2003-02-10 | 2004-08-26 | Elan Pharmaceuticals, Inc. | Immunoglobulin formulation and method of preparation thereof |
ES2383691T3 (en) | 2003-12-23 | 2012-06-25 | Pharmacia Corporation | Stable liquid formulation of growth hormones |
US7816320B2 (en) * | 2004-12-22 | 2010-10-19 | Ambrx, Inc. | Formulations of human growth hormone comprising a non-naturally encoded amino acid at position 35 |
DK1899462T3 (en) * | 2005-07-02 | 2011-06-06 | Arecor Ltd | Stable aqueous systems comprising proteins |
JP2009521486A (en) * | 2005-12-23 | 2009-06-04 | アルタス ファーマシューティカルズ インコーポレイテッド | Composition comprising polycation complexed protein crystals and therapeutic method using the same |
US20090136538A1 (en) * | 2006-05-22 | 2009-05-28 | Jan Jezek | Stable vaccine formulation |
BRPI0621841B8 (en) * | 2006-07-06 | 2021-05-25 | Daewoong Co Ltd | liquid formulation |
GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
AU2008262490B2 (en) | 2007-05-22 | 2011-11-17 | Amgen Inc. | Compositions and methods for producing bioactive fusion proteins |
EP2283027B2 (en) * | 2008-05-01 | 2018-04-18 | Arecor Limited | Protein formulation |
EP2341940A1 (en) * | 2008-07-16 | 2011-07-13 | Arecor Limited | The stabilisation of proteins |
EP2328607A1 (en) * | 2008-07-16 | 2011-06-08 | Arecor Limited | Stable formulation of a therapeutic protein |
WO2010096394A2 (en) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Aldehyde-tagged protein-based drug carriers and methods of use |
US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
RS52367B (en) * | 2009-07-15 | 2012-12-31 | Teva Pharmaceutical Industries Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
CZ29723U1 (en) | 2009-08-20 | 2016-08-30 | Yeda Research & Development Company, Ltd. | Low frequency glatiramer acetate therapy |
USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
KR101337797B1 (en) * | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | A liquid formulation of long acting human growth hormone conjugate |
AU2012205301B2 (en) | 2011-01-14 | 2017-01-05 | Redwood Bioscience, Inc. | Aldehyde-tagged immunoglobulin polypeptides and method of use thereof |
US20140194356A1 (en) * | 2011-07-25 | 2014-07-10 | Sandoz Ag | Aqueous formulation comprising at least a neutral salt and a biopharmaceutical protein |
CN102302446B (en) * | 2011-09-08 | 2013-04-17 | 安徽安科生物工程(集团)股份有限公司 | Recombinant human growth hormone injection capable of being directly used |
US10064951B2 (en) * | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
EP3319930A4 (en) * | 2015-07-07 | 2019-04-10 | NanoBio Corporation | Methods and compositions for the stabilizaton of proteins |
US11173197B2 (en) | 2015-07-07 | 2021-11-16 | Bluewillow Biologics, Inc. | Methods and compositions for nanoemulsion vaccine formulations |
AU2017257504A1 (en) | 2016-04-26 | 2018-10-25 | R.P. Scherer Technologies, Llc | Antibody conjugates and methods of making and using the same |
US11167003B2 (en) | 2017-03-26 | 2021-11-09 | Mapi Pharma Ltd. | Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (PPMS or SPMS) using sustained release glatiramer depot systems |
Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3928137A (en) * | 1971-10-20 | 1975-12-23 | Mallinckrodt Inc | Reagent formulation for uric acid assay |
US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4188373A (en) * | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4297344A (en) * | 1979-04-25 | 1981-10-27 | Behringwerke Aktiengesellschaft | Blood coagulation factors and process for their manufacture |
US4357310A (en) * | 1980-08-08 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Method and composition for reducing the nonspecific binding of radioiodinated protein hormones |
US4474752A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474753A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4637834A (en) * | 1983-07-13 | 1987-01-20 | Hoechst Aktiengesellschaft | Aqueous protein solutions which are stable towards denaturing, processes for their preparation and their use |
US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
US4812557A (en) * | 1984-04-09 | 1989-03-14 | Takeda Chemical Industries | Stable composition of interleukin-2 and human serum albumin |
US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
US4857506A (en) * | 1987-01-12 | 1989-08-15 | American Cyanamid Company | Sustained release growth hormone compositions for parenteral administration and their use |
US4857505A (en) * | 1987-03-09 | 1989-08-15 | American Cyanamid Company | Sustained release compositions for parenteral administration and their use |
US4917685A (en) * | 1986-05-16 | 1990-04-17 | International Minerals & Chem. Corp. | Delivery device for the administration of stabilized growth promoting hormones |
US4992419A (en) * | 1987-05-09 | 1991-02-12 | Boehringer Mannheim Gmbh | Stabilized erythropoietin preparations |
US5008244A (en) * | 1989-05-15 | 1991-04-16 | Pitman-Moore, Inc. | Method for increasing fertility in animals |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5317012A (en) * | 1991-10-04 | 1994-05-31 | The University Of Tennessee Research Corporation | Human growth hormone induced improvement in depressed T4/T8 ratio |
US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
US5567677A (en) * | 1992-04-03 | 1996-10-22 | Pharmacia Ab | Protein formulation comprising growth hormone |
US5597802A (en) * | 1990-06-07 | 1997-01-28 | Genentech, Inc. | Method of formulating IGF-I with growth hormone |
US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US6448225B2 (en) * | 1988-04-15 | 2002-09-10 | Genentech, Inc. | Human growth hormone aqueous formulation |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3064888D1 (en) * | 1979-04-30 | 1983-10-27 | Hoechst Ag | Aqueous solutions of proteins stable against denaturization, process for their manufacture, and their utilization |
EP0193917A3 (en) * | 1985-03-06 | 1987-09-23 | American Cyanamid Company | Water dispersible and water soluble carbohydrate polymer compositions for parenteral administration |
PT83095B (en) * | 1985-07-30 | 1987-12-23 | Int Minerals & Chem Corp | Method for the stabilization of growth promoting hormones using polyoxyethylene-polyoxypropylene copolymers |
GR871067B (en) | 1986-07-18 | 1987-11-19 | Chugai Pharmaceutical Co Ltd | Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor |
ES2044941T5 (en) * | 1987-08-21 | 1999-02-16 | Mallinckrodt Group Inc | STABILIZER OF GROWTH PROMOTING HORMONES. |
IL88233A (en) | 1987-11-03 | 1993-08-18 | Genentech Inc | Gamma interferon formulation |
NO179479C (en) * | 1988-03-11 | 1996-10-16 | Teikoku Seiyaku Kk | Process for the preparation of an intravaginal pharmaceutical preparation |
FR2630115B1 (en) | 1988-04-14 | 1994-10-28 | Merieux Inst | PROCESS FOR STABILIZING HUMAN ALBUMIN SOLUTIONS AND SOLUTION OBTAINED |
JPH01308235A (en) * | 1988-06-03 | 1989-12-12 | Yamanouchi Pharmaceut Co Ltd | Human growth hormone for transnasal administration |
EP0374120A3 (en) * | 1988-12-13 | 1991-07-31 | Monsanto Company | Comosition for controlled release of polypeptides |
CA2020654A1 (en) * | 1989-07-07 | 1991-01-08 | Yohko Akiyama | Stabilized fgf composition and production thereof |
IN172427B (en) * | 1989-11-14 | 1993-07-24 | Fidia Spa | |
GB9007052D0 (en) | 1990-03-29 | 1990-05-30 | Skua Investments Ltd | Pharmaceutical formulations |
US5217954A (en) * | 1990-04-04 | 1993-06-08 | Scios Nova Inc. | Formulations for stabilizing fibroblast growth factor |
US5210017A (en) | 1990-11-19 | 1993-05-11 | Genentech, Inc. | Ligand-mediated immunofunctional hormone binding protein assay method |
AU1757092A (en) * | 1991-03-28 | 1992-11-02 | Genentech Inc. | Stable growth hormone metal ion formulations |
AU2147192A (en) * | 1991-06-28 | 1993-01-25 | Genentech Inc. | Method of stimulating immune response using growth hormone |
DK204791D0 (en) * | 1991-12-20 | 1991-12-20 | Novo Nordisk As | UNKNOWN PHARMACEUTICAL PREPARATION |
WO1993019773A1 (en) | 1992-04-07 | 1993-10-14 | Pitman-Moore, Inc. | Lyophilized somatotropin formulations |
AU679913B2 (en) * | 1992-04-30 | 1997-07-17 | Millennium Pharmaceuticals, Inc. | Stable polypeptide composition |
ATE359824T1 (en) * | 1992-07-31 | 2007-05-15 | Genentech Inc | AQUEOUS FORMULATION CONTAINING HUMAN GROWTH HORMONE |
US6277828B1 (en) | 1993-08-20 | 2001-08-21 | Syntex (U.S.A.) Inc. | Pharmaceutical formulations of nerve growth factor |
JPH0892125A (en) * | 1994-09-21 | 1996-04-09 | Nippon Chem Res Kk | Aqueous medicine composition |
US20020077461A1 (en) * | 1996-04-24 | 2002-06-20 | Soren Bjorn | Pharmaceutical formulation |
-
1997
- 1997-07-14 US US08/891,823 patent/US5981485A/en not_active Expired - Lifetime
-
1999
- 1999-06-25 US US09/344,225 patent/US6448225B2/en not_active Expired - Fee Related
-
2002
- 2002-07-01 US US10/186,775 patent/US20030013653A1/en not_active Abandoned
-
2005
- 2005-08-08 US US11/199,314 patent/US20050272657A1/en not_active Abandoned
-
2006
- 2006-09-28 US US11/529,677 patent/US20070027083A1/en not_active Abandoned
-
2009
- 2009-01-15 US US12/321,084 patent/US20090163419A1/en not_active Abandoned
-
2011
- 2011-06-01 US US13/150,911 patent/US20110230408A1/en not_active Abandoned
-
2013
- 2013-02-21 US US13/772,773 patent/US20130165378A1/en not_active Abandoned
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3928137A (en) * | 1971-10-20 | 1975-12-23 | Mallinckrodt Inc | Reagent formulation for uric acid assay |
US4100271A (en) * | 1976-02-26 | 1978-07-11 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4188373A (en) * | 1976-02-26 | 1980-02-12 | Cooper Laboratories, Inc. | Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes |
US4297344A (en) * | 1979-04-25 | 1981-10-27 | Behringwerke Aktiengesellschaft | Blood coagulation factors and process for their manufacture |
US4783441A (en) * | 1979-04-30 | 1988-11-08 | Hoechst Aktiengesellschaft | Aqueous protein solutions stable to denaturation |
US4623717A (en) * | 1980-03-05 | 1986-11-18 | Miles Laboratories, Inc. | Pasteurized therapeutically active protein compositions |
US4357310A (en) * | 1980-08-08 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Method and composition for reducing the nonspecific binding of radioiodinated protein hormones |
US4474752A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Drug delivery system utilizing thermosetting gels |
US4474753A (en) * | 1983-05-16 | 1984-10-02 | Merck & Co., Inc. | Topical drug delivery system utilizing thermosetting gels |
US4637834A (en) * | 1983-07-13 | 1987-01-20 | Hoechst Aktiengesellschaft | Aqueous protein solutions which are stable towards denaturing, processes for their preparation and their use |
US4812557A (en) * | 1984-04-09 | 1989-03-14 | Takeda Chemical Industries | Stable composition of interleukin-2 and human serum albumin |
US4917685A (en) * | 1986-05-16 | 1990-04-17 | International Minerals & Chem. Corp. | Delivery device for the administration of stabilized growth promoting hormones |
US4816568A (en) * | 1986-05-16 | 1989-03-28 | International Minerals & Chemical Corp. | Stabilization of growth hormones |
US4857506A (en) * | 1987-01-12 | 1989-08-15 | American Cyanamid Company | Sustained release growth hormone compositions for parenteral administration and their use |
US4857505A (en) * | 1987-03-09 | 1989-08-15 | American Cyanamid Company | Sustained release compositions for parenteral administration and their use |
US4992419A (en) * | 1987-05-09 | 1991-02-12 | Boehringer Mannheim Gmbh | Stabilized erythropoietin preparations |
US5096885A (en) * | 1988-04-15 | 1992-03-17 | Genentech, Inc. | Human growth hormone formulation |
US20050272657A1 (en) * | 1988-04-15 | 2005-12-08 | Genentech, Inc. | Human growth hormone aqueous formulation |
US6448225B2 (en) * | 1988-04-15 | 2002-09-10 | Genentech, Inc. | Human growth hormone aqueous formulation |
US5763394A (en) * | 1988-04-15 | 1998-06-09 | Genentech, Inc. | Human growth hormone aqueous formulation |
US5182258A (en) * | 1989-03-20 | 1993-01-26 | Orbon Corporation | Systemic delivery of polypeptides through the eye |
US5008244A (en) * | 1989-05-15 | 1991-04-16 | Pitman-Moore, Inc. | Method for increasing fertility in animals |
US5597802A (en) * | 1990-06-07 | 1997-01-28 | Genentech, Inc. | Method of formulating IGF-I with growth hormone |
US5374620A (en) * | 1990-06-07 | 1994-12-20 | Genentech, Inc. | Growth-promoting composition and its use |
US5126324A (en) * | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
US5317012A (en) * | 1991-10-04 | 1994-05-31 | The University Of Tennessee Research Corporation | Human growth hormone induced improvement in depressed T4/T8 ratio |
US5567677A (en) * | 1992-04-03 | 1996-10-22 | Pharmacia Ab | Protein formulation comprising growth hormone |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180206890A1 (en) * | 2017-01-25 | 2018-07-26 | Warsaw Orthopedic, Inc | Spinal implant system and methods of use |
Also Published As
Publication number | Publication date |
---|---|
US5981485A (en) | 1999-11-09 |
US20050272657A1 (en) | 2005-12-08 |
US6448225B2 (en) | 2002-09-10 |
US20130165378A1 (en) | 2013-06-27 |
US20010007858A1 (en) | 2001-07-12 |
US20090163419A1 (en) | 2009-06-25 |
US20030013653A1 (en) | 2003-01-16 |
US20110230408A1 (en) | 2011-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6448225B2 (en) | Human growth hormone aqueous formulation | |
CA2337745C (en) | Human growth hormone aqueous formulation | |
US5763394A (en) | Human growth hormone aqueous formulation | |
EP0970703B1 (en) | Use of metal chelating agents to stabilize preparations containing interferon | |
US7144861B2 (en) | Stabilized teriparatide solutions | |
US20010027180A1 (en) | GLP-2 formulations | |
JP4353544B2 (en) | Amylin agonist peptide formulation | |
US20010043934A1 (en) | Formulations for amylin agonist peptides | |
LT4051B (en) | Pharmaceutical formulations of nerve growth factor | |
JP4255515B2 (en) | Stabilized growth hormone formulation and method for producing the same | |
JP2003504346A (en) | Growth hormone preparations | |
CN115364060A (en) | Freeze-dried medicinal preparation and application thereof | |
JP4949828B2 (en) | Stabilization of growth hormone in solution | |
MXPA03008545A (en) | Pharmaceutical compositions containing human growth hormone. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |